14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EYEG vs XBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EYEG carries a Unified Composite Score of 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin).
Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. XBIO 43.5/100 HOLD), XBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-81.0% vs. N/A operating margin) and revenue trajectory (+12.0% vs. N/A YoY).
Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EYEG vs XBIO. Trailing 12-month operating profitability (EYEG N/A vs XBIO -81.0%) and valuation multiples (EYEG N/M vs XBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6M market capitalization and -81.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EYEG vs XBIO Key Questions & Quantitative Answers
As of Nov 20, 2026, Xenetic Biosciences, Inc. (XBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EYEG carries a Unified Composite Score of 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin), whereas XBIO carries 43.5/100 (HOLD) at $1.40 (N/M Forward P/E, -81.0% operating margin). Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. XBIO 43.5/100 HOLD), XBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-81.0% vs. N/A operating margin) and revenue trajectory (+12.0% vs. N/A YoY). Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile XBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XBIO leads the Growth & Scale pillar: EYEG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XBIO at +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin). On trailing 12-month operating scale, EYEG generates N/A in USD-normalized revenue versus $3.3M for XBIO. In operating R&D and SG&A reinvestment, EYEG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBIO.
XBIO screens cheaper on headline valuation multiples. EYEG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-55.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EYEG (N/A ROE) versus XBIO (-47.0% ROE) capital efficiency.
In options market volatility and institutional positioning, EYEG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.13β · 5% Vol realized risk). By comparison, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 99% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.